Navneet S. Majhail

Sarah Cannon — United States

Medicine · Health Sciences

72h-index18.0kcitations696works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(306), Acute Lymphoblastic Leukemia research(225), Acute Myeloid Leukemia Research(118), Childhood Cancer Survivors' Quality of Life(101), CAR-T cell therapy research(66)

Publications695 total

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene
Blood·2026
Outpatient Versus Inpatient Axicabtagene Ciloleucel CAR T-Cell Therapy in Non-Hodgkin’s Lymphoma: Insights from a US Multicenter Transplant and Cellular Therapy Network
Transplantation and Cellular Therapy·2026
Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Blood Immunology & Cellular Therapy·2025Open Access
A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation
Blood·2025Open Access
Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world
Blood·2025Open Access
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Bone Marrow Transplantation·2025· 1 citedOpen Access
Financial Toxicity, Psychological Well-Being, and Quality of Life in Hematopoietic Stem Cell Transplantation
Transplantation and Cellular Therapy·2025· 3 cited
Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee
UNC Libraries·2025Open Access
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation
Transplantation and Cellular Therapy·2025· 3 cited
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement
Blood Advances·2025· 2 citedOpen Access
Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring
JCO Oncology Practice·2025· 4 cited
Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma
Transplantation and Cellular Therapy·2025· 3 cited
KMT2Ar Adversely Impacts Brexucabtagene Autoleucel (Brexu-cel) Outcome in Adults with Relapsed/ Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia.
Transplantation and Cellular Therapy·2025· 1 cited
Remote Patient Monitoring for 15 Vs. 30 Days in Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System
Transplantation and Cellular Therapy·2025
CAR and ALL Hematotox Scores Predict Toxicity and Outcomes Among Recipients of Brexucabtagene Autoleucel for R/R ALL in the Real World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) Consortium
Transplantation and Cellular Therapy·2025
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
Transplantation and Cellular Therapy·2025
Tyrosine Kinase Inhibitor (TKI) Maintenance Improves Remission Durability in Philadelphia-Chromosome Acute Lymphoblastic Leukemia (Ph+ ALL) Following Brexucabtagene Autoleucel (Brexu-cel)
Transplantation and Cellular Therapy·2025· 1 cited
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Transplantation and Cellular Therapy·2025Open Access
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis
Transplantation and Cellular Therapy·2025· 3 citedOpen Access
Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System
Blood·2024· 1 citedOpen Access
page 1 of 35Next →

Frequent Co-authors

Bipin N. Savani(14), J. Douglas Rizzo(12), John R. Wingard(10), Linda J. Burns(10), Hillard M. Lazarus(10), Christopher Bredeson(9), Stephanie J. Lee(8), Paul A. Carpenter(7), Daniel J. Weisdorf(7), David A. Jacobsohn(6), Gèrard Socié(6), David I. Marks(6), Mahmoud Aljurf(6), Rammurti T. Kamble(6), William A. Wood(6), Mary M. Horowitz(5), Richard E. Champlin(5), Sergio Giralt(5), Mehdi Hamadani(5), Theresa Hahn(5)